BeOne Medicines
264 hedge funds and large institutions have $15B invested in BeOne Medicines in 2021 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 84 increasing their positions, 91 reducing their positions, and 33 closing their positions.
9% more funds holding in top 10
Funds holding in top 10: 11 → 12 (+1)
4% more funds holding
Funds holding: 255 → 264 (+9)
6% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 33
0.92% less ownership
Funds ownership: 55.12% → 54.19% (-0.92%)
8% less repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 91
53% less capital inflows, than outflows
Capital inflows: $288M | Capital outflows: $614M
77% less call options, than puts
Call options by funds: $28.3M | Put options by funds: $125M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Indus Capital Partners
New York
|
+$30.4M |
| 2 |
Bridgewater Associates
Westport,
Connecticut
|
+$18.1M |
| 3 |
Zeal Asset Management
Central,
Hong Kong
|
+$18M |
| 4 |
Segantii Capital Management
Hong Kong
|
+$15.5M |
| 5 |
BSN Capital Partners
London,
United Kingdom
|
+$14.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Boxer Capital Management
San Diego,
California
|
-$89.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$63M |
| 3 |
Public Investment Fund
Al Aqiq District, Riyadh,
Saudi Arabia
|
-$60M |
| 4 |
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$44.9M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$42.3M |
ONC Hedge Fund Activity: Q4 2021 in Review
264 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines (ONC) for Q4 2021, worth a combined $15B — down 26% from $20.4B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new ONC positions and 33 closed out — a net gain of 2 holders — while 84 added to existing stakes and 91 trimmed.
The largest buyer was Indus Capital Partners, adding an estimated $30.4M. The largest seller was Boxer Capital Management, cutting an estimated $89.2M.
- 264 institutional investors held BeOne Medicines (ONC) as of Q4 2021, up from 255 in Q3 2021.
- Funds reported $15B of BeOne Medicines stock for Q4 2021, down 26% quarter-over-quarter.
- 35 funds opened new BeOne Medicines positions in Q4 2021 and 33 closed out, a net change of +2 holders.
- The largest BeOne Medicines buyer in Q4 2021 was Indus Capital Partners, an estimated $30.4M added.
- The largest BeOne Medicines seller in Q4 2021 was Boxer Capital Management, an estimated $89.2M sold.
Based on aggregated 13F filings for Q4 2021.